{"id":"pembrolizumab-quavonlimab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Muscle or joint pain"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Itching"},{"rate":"5-10%","effect":"Hypothyroidism"},{"rate":"5-10%","effect":"Increased liver enzymes"},{"rate":"5-10%","effect":"Decreased white blood cell count"},{"rate":"5-10%","effect":"Decreased platelet count"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pembrolizumab is a monoclonal antibody that targets the PD-1 protein, preventing it from interacting with its ligands and thereby releasing the brakes on the immune system. Quavonlimab is a monoclonal antibody that targets the TIGIT protein, which is also involved in the regulation of the immune response. By blocking these proteins, pembrolizumab/quavonlimab allows the immune system to attack and kill cancer cells more effectively.","oneSentence":"Pembrolizumab/Quavonlimab is a combination of a PD-1 inhibitor and a TIGIT inhibitor, which works by blocking the PD-1 and TIGIT proteins to enhance the body's immune response against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:31.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic non-small cell lung cancer"},{"name":"Locally advanced or metastatic small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04938817","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-19","conditions":"Small Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT04895722","phase":"PHASE2","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-25","conditions":"Colorectal Cancer","enrollment":302},{"nctId":"NCT04626479","phase":"PHASE1, PHASE2","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-16","conditions":"Carcinoma, Renal Cell","enrollment":400},{"nctId":"NCT05899049","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-27","conditions":"Carcinoma, Renal Cell","enrollment":249},{"nctId":"NCT04700072","phase":"PHASE1, PHASE2","title":"Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-03","conditions":"Melanoma","enrollment":56},{"nctId":"NCT04305054","phase":"PHASE1, PHASE2","title":"Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Melanoma","enrollment":315},{"nctId":"NCT04305041","phase":"PHASE1, PHASE2","title":"Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":100},{"nctId":"NCT04740307","phase":"PHASE2","title":"Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-16","conditions":"Advanced Hepatocellular Carcinoma","enrollment":116},{"nctId":"NCT04626518","phase":"PHASE1, PHASE2","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-17","conditions":"Carcinoma, Renal Cell","enrollment":370},{"nctId":"NCT03516981","phase":"PHASE2","title":"A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-01","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":245},{"nctId":"NCT03179436","phase":"PHASE1, PHASE2","title":"Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-07-02","conditions":"Advanced Solid Tumors","enrollment":415},{"nctId":"NCT04736706","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-14","conditions":"Carcinoma, Renal Cell","enrollment":1653}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-1308A"],"phase":"phase_3","status":"active","brandName":"Pembrolizumab/Quavonlimab","genericName":"Pembrolizumab/Quavonlimab","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pembrolizumab/Quavonlimab is a combination of a PD-1 inhibitor and a TIGIT inhibitor, which works by blocking the PD-1 and TIGIT proteins to enhance the body's immune response against cancer cells. Used for Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}